Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MAZE Catalyst Timeline
Dated clinical, regulatory and corporate events for Maze Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Maze Therapeutics, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How MAZE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-24 | MZE829 | Phase 2 data presentation | Phase 2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MZE829 Small MoleculesNCT06830629 | Proteinuric Kidney Disease | Phase 2 | RECRUITING | 74 | Sep 1, 2026 | ||||||
| MZE782 Small MoleculesNCT07694440 | Phenylketonuria (PKU) | Phase 2 | RECRUITING | 38 | Feb 1, 2028 | ||||||
| MZE001 Small MoleculesCompletedNCT05249621 | Undisclosed | Phase 1 | COMPLETED | 121 | Dec 21, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every MAZE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Coloma Jason VDirector, Officer (Chief Executive Officer) | Sell | -2,257 13,301 held | $30.12 | 11/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MAZE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3.6 % (9.1 %) | 143.59 M | 5.28 M | 4.97% ( 250.00 K) |
Ownership Trends
MAZE Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How MAZE ranks across every disease it competes in
MAZE News
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics reported its Q3 2026 financial results, highlighting the completion of enrollment in the Phase 2 HORIZON trial for MZE829. The company anticipates data from this trial in early 2027. Additionally, Maze is progressing with MZE782 in ongoing trials for PKU and CKD, with plans for further trials in 2027. The company's financial position remains strong with $477 million in cash.
Read more →Maze Therapeutics to Participate in Upcoming Investor Conferences
Maze Therapeutics announced participation in three upcoming investor conferences. CEO Jason Coloma will engage in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 10, 2026. He will also present at the Jefferies Global Healthcare Conference in London on November 17, 2026, and at the Evercore Healthcare Conference on December 1, 2026.
Read more →Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Maze Therapeutics will present data from its MZE829 and MZE782 programs at ASN Kidney Week 2026. The oral presentation will focus on updated Phase 2 HORIZON trial results for MZE829 in patients with APOL1-mediated kidney disease. Additionally, two poster presentations will discuss preclinical research on SLC6A19 inhibition's therapeutic potential for chronic kidney disease.
Read more →Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics, a clinical-stage biopharmaceutical company, will participate in three investor conferences in September 2026. The events include the Wells Fargo Annual Healthcare Conference, Citi Biopharma Summit, and H.C. Wainwright Global Investment Conference. Live webcasts of these presentations will be available on their website. The company is developing precision medicines targeting kidney and metabolic diseases.
Read more →Maze Therapeutics Announces Appointments to Its Board of Directors
Maze Therapeutics has appointed Paula Johnson, M.D., and Sophie Kornowski, Pharm.D., to its Board of Directors. These appointments aim to enhance the company's clinical and business expertise as it advances its pipeline, including key milestones for drug candidates MZE829 and MZE782 expected in the coming years. The company focuses on developing precision medicines for kidney and metabolic diseases.
Read more →Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics reported a net loss of $44.7 million for the second quarter ended June 30, 2026. The company holds $495 million in cash and marketable securities to fund operations through 2029. Enrollment in the Phase 2 HORIZON trial for MZE829 remains on track. Data from all cohorts is expected in late 2026 or early 2027.
Read more →Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. CEO Jason Coloma will present at the Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs Global Healthcare Conference on June 10, 2026. The company is known for developing precision medicines for kidney and metabolic diseases.
Read more →Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics reported positive topline data from its Phase 2 HORIZON trial of MZE829, supporting its advancement into pivotal trials. The company is also on track to initiate Phase 2 trials for MZE782 targeting PKU and CKD. With a strong cash position of $528 million, Maze aims to continue its clinical execution through 2029.
Read more →Maze Therapeutics Announces $150 Million Registered Offering
Maze Therapeutics announced a $150 million registered offering of its common stock at $23.50 per share. The offering includes pre-funded warrants and is expected to close on April 23, 2026. The funds will primarily be used for the development of MZE829 and MZE782, targeting kidney and metabolic diseases. The offering has attracted both new and existing investors.
Read more →Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Maze Therapeutics reported strong financial results for Q4 and full year 2025, highlighting positive topline data from the Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease. The company plans to advance MZE829 into a pivotal program and initiate two Phase 2 trials for MZE782 in PKU and CKD in 2026. Additionally, Neil Kumar has joined the Board of Directors, enhancing the company's leadership.
Read more →Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
Maze Therapeutics announced positive topline data from the Phase 2 HORIZON trial of MZE829, showing a significant mean reduction in proteinuria in patients with broad APOL1-mediated kidney disease. At week 12, MZE829 led to a 35.6% reduction in uACR, with half of the patients achieving greater than 30% reduction. The treatment was well-tolerated, and the company plans to advance MZE829 into a pivotal program.
Read more →Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Maze Therapeutics, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. CEO Jason Coloma, Ph.D., will lead the presentation, which will also be available via live webcast. The company focuses on developing precision medicines for kidney and metabolic diseases.
Read more →Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Maze Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026, showcasing its advancements in precision medicines for kidney and metabolic diseases. CEO Jason Coloma will speak on February 11, 2026. The company is known for its innovative approach using human genetics to develop treatments, with key products in Phase 2 development.
Read more →Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Maze Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Jason Coloma, Ph.D., will discuss the company's advancements in small molecule precision medicines for kidney and metabolic diseases. The event will be available via live webcast and archived for 30 days.
Read more →Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Maze Therapeutics reported strong financial results for Q3 2025, highlighting positive first-in-human data from its Phase 1 trial of MZE782. The company plans to initiate two Phase 2 trials in 2026 for MZE782 targeting phenylketonuria and chronic kidney disease. Additionally, the ongoing Phase 2 HORIZON trial of MZE829 is expected to provide topline data by the end of Q1 2026.
Read more →Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
Maze Therapeutics announced seven presentations at ASN Kidney Week, showcasing advancements in their MZE782 and MZE829 programs. MZE782, a novel SLC6A19 inhibitor, is in Phase 1 trials for PKU and CKD, while MZE829 is in Phase 2 for APOL1-mediated kidney disease. The company emphasizes the importance of genetic insights in developing effective therapies.
Read more →Maze Therapeutics to Participate in Four Upcoming Investor Conferences
Maze Therapeutics announced that its management will participate in four upcoming investor conferences. The company will present at the Guggenheim Healthcare Innovation Conference on November 11. Additional appearances are scheduled for the TD Cowen Immunology Summit on November 13. The Jefferies Global Healthcare Conference follows on November 20, and the Evercore Healthcare Conference is set for December 3.
Read more →Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Maze Therapeutics has appointed Hervé Hoppenot as the new Chairman of the Board, succeeding Charles Homcy, M.D. Hoppenot, who has extensive experience in the biopharmaceutical industry, expressed his commitment to advancing the company's clinical programs, particularly MZE782 and MZE829. The company is well-positioned for growth with recent funding and promising clinical data.
Read more →Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
Maze Therapeutics has announced a successful oversubscribed private placement, raising approximately $150 million. The funds will be used to further develop its lead candidates, MZE829 and MZE782, targeting kidney and metabolic diseases. The placement involves participation from both new and existing investors and is set to close on September 12, 2025.
Read more →Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
Maze Therapeutics announced positive Phase 1 trial results for MZE782, an oral SLC6A19 inhibitor. The trial demonstrated significant increases in urinary phenylalanine excretion and a favorable safety profile, supporting its advancement to Phase 2 trials for treating phenylketonuria (PKU) and chronic kidney disease (CKD) expected to start in 2026.
Read more →